secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001093557-23-000117
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q1 revenue $741.5M (+18% YoY); raises FY 2023 guidance to $3.4-3.515B
----------------------------------------------------------------------------

- Revenue $741.5M (+18% YoY, +19% organic); US +17%, Intl +21% reported (+27% organic).
- GAAP net income $48.6M ($0.12 diluted EPS); Non-GAAP net income $68.5M ($0.17 diluted EPS).
- GAAP operating income $47.2M (6.4% revenue); Non-GAAP operating income $78.6M (10.6% revenue).
- Initiated Dexcom G7 launch in US; CMS finalized coverage for G7 for Medicare beneficiaries.
- FY 2023 revenue guidance raised to $3.4-3.515B (17-21% growth); margin guidance reiterated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/0001093557-23-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/dxcm-20230427.htm
  HTML page:      https://secwatch.observer/filing/0001093557-23-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer